CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status

摘要

In this phase II, randomized, open label study the efficacy and tolerability of panitumumab in combination with pemetrexed/cisplatin versus pemetrexed/cisplatin in patients with stage IIIB/IV primary nonsquamous nonesmall-cell lung cancer and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog were assessed. The overall survival showed a clear difference between the treatment groups in favor of the standard therapy. This study teaches important lessons for future trial design.